{'fraction_non_alphanumeric': 0.027675276752767528, 'fraction_numerical': 0.01014760147601476, 'mean_word_length': 5.656441717791411, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hodgkin's disease therapeutic program.

In 1963, prompted by the early success of the use of combinations of drugs for the treatment of acute childhood leukemia, a pilot study was performed using combinations of drugs in Hodgkin's disease (vinca alkaloids, alkylating agents, prednisone, and methotrexate). The results were encouraging enough to lead to an expanded program substituting procarbazine hydrochloride for methotrexate. This combined-drug program (MOPP) nine years later has yielded results significantly different than those previously achieved with single agents. The results of this program, employing combinations of effective drugs, consistently show a higher rate of induction of complete remissions in patients with advanced Hodgkin's disease (80%, compared with 25%) and prolongation of remission duration after all therapy is stopped (36 months, compared with 3 months). These results have been confirmed in several cooperative trials. With a doubling or tripling of the complete remission rate and an eightto ten-fold increase in remission duration after therapy